Seres Therapeutics, Inc. Share Price & Technical Analysis
MCRB · $7.92 (-1.61%)
Healthcare / Biotechnology
$7.92
-1.61%
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pati…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
7% return in May, -9% avg return in past 3 year May month.
-52% return in 2026, -26% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | -42% | 2% | -18% | 7% | – | – | – | – | – | – | – | -52% |
| 25 | -1% | -11% | -8% | -31% | -28% | 56% | 29% | 35% | 2% | -19% | 13% | -15% | 23% |
| 24 | -18% | -1% | -33% | 27% | -2% | -27% | 76% | -41% | 17% | 0% | 24% | -18% | 5% |
| 23 | -5% | -8% | 13% | -15% | 2% | -4% | 0% | -28% | -32% | -36% | -31% | 37% | -106% |
| 22 | 1% | -4% | -8% | -34% | -35% | 9% | 23% | 27% | 27% | 37% | -28% | -15% | -1% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$75.05M
P/E ratio
—
52W high
$29.98
52W low
$6.56
Volume
21,029
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Seres Therapeutics, Inc. share price today?
- Seres Therapeutics, Inc. (MCRB) last traded around $7.92 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MCRB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MCRB. Download the app for real-time alerts.
- How can I analyze Seres Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.